Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
Advanced Biomed (Nasdaq: ADVB) has launched A+PerfusC™, an integrated perfusion 3D cell culture platform designed for precision medicine and drug discovery applications. The system features a compact, all-in-one design that supports up to 12 days of continuous, hands-free culture with capacity for 4,800 tumor spheroids per plate.
Key features include 8 independent channels per plate, compatibility with 96/384 well plates for high-throughput screening, and microscope mounting capability. The platform has completed internal testing and validation, with mass production development currently underway.
The launch targets the growing global 3D cell culture market, valued at $2.32 billion in 2025 and projected to reach $4.71 billion by 2030, with a CAGR of 15.6%.
Advanced Biomed (Nasdaq: ADVB) ha lanciato A+PerfusC™, una piattaforma integrata di coltura cellulare 3D tramite perfusione progettata per la medicina di precisione e la scoperta di farmaci. Il sistema presenta un design compatto tutto-in-uno che supporta fino a 12 giorni di coltura continua e senza intervento, con una capacità di 4.800 sfere tumorali per piatto.
Caratteristiche chiave: 8 canali indipendenti per piatto, compatibilità con piastre da 96/384 ben per lo screening ad alto rendimento e possibilità di montaggio al microscopio. La piattaforma ha superato i test interni e la validazione, e lo sviluppo per la produzione di massa è attualmente in corso.
Il lancio è rivolto al crescente mercato globale della coltura cellulare 3D, valutato 1,232 miliardi di dollari nel 2025 e previsto raggiungere 4,71 miliardi di dollari entro il 2030, con un CAGR del 15,6%.
Advanced Biomed (Nasdaq: ADVB) ha lanzado A+PerfusC™, una plataforma integrada de cultivo celular 3D por perfusión diseñada para la medicina de precisión y la descubrimiento de fármacos. El sistema presenta un diseño compacto todo-en-uno que admite hasta 12 días de cultivo continuo y sin intervención, con capacidad para 4.800 esferoides tumorales por placa.
Las características clave incluyen 8 canales independientes por placa, compatibilidad con placas de 96/384 pocillos para cribado de alto rendimiento, y capacidad para montaje en microscopio. La plataforma ha superado pruebas internas y validación, y el desarrollo para la producción en masa está en curso.
El lanzamiento apunta al creciente mercado global de cultivo celular 3D, valorado en 2.32 mil millones de dólares en 2025 y previsto alcanzar 4.71 mil millones de dólares para 2030, con una tasa de crecimiento anual compuesta (CAGR) del 15.6%.
Advanced Biomed (Nasdaq: ADVB)는 정밀 의학 및 신약 발견 응용을 위해 설계된 통합 순환 3D 세포배양 플랫폼인 A+PerfusC™를 출시했습니다. 이 시스템은 4,800개의 종양 구(구체)를 한 접시당 수용할 수 있는 12일간의 연속 무손실 배양을 지원하는 콤팩트한 올인원 디자인을 특징으로 합니다.
주요 특징으로는 접시당 8개의 독립 채널, 고처리량 스크리닝을 위한 96/384 웰 플레이트와의 호환성, 현미경 장착 가능성이 있습니다. 플랫폼은 내부 테스트 및 검증을 완료했으며, 대량 생산 개발이 현재 진행 중입니다.
출시는 글로벌 3D 세포배양 시장의 성장에 초점을 두고 있으며, 2025년 가치는 23.2억 달러로 추정되며 2030년에는 47.1억 달러에 이를 것으로 예상되며 CAGR은 15.6%입니다.
Advanced Biomed (Nasdaq : ADVB) a lancé A+PerfusC™, une plateforme intégrée de culture cellulaire 3D par perfusion conçue pour la médecine de précision et la découverte de médicaments. Le système présente un design compact tout-en-un qui supporte jusqu’à 12 jours de culture continue et sans intervention, avec une capacité de 4 800 sphéroïdes tumoraux par plaque.
Les caractéristiques clés incluent 8 canaux indépendants par plaque, la compatibilité avec des plaques de 96/384 puits pour le criblage à haut débit et une capacité de montage au microscope. La plateforme a passé les tests internes et la validation, et le développement pour la production de masse est en cours.
Le lancement vise le marché mondial croissant de la culture cellulaire 3D, évalué à 2,32 milliards de dollars en 2025 et projeté à 4,71 milliards de dollars d’ici 2030, avec un CAGR de 15,6%.
Advanced Biomed (Nasdaq: ADVB) hat A+PerfusC™ vorgestellt, eine integrierte Perfusions-Plattform für die 3D-Zellkultur, konzipiert für Präzisionsmedizin und Wirkstoffentdeckung. Das System verfügt über ein kompaktes All-in-One-Design, das bis zu 12 Tage kontinuierliche, freihändige Kultur unterstützt, mit einer Kapazität von 4.800 Tumor-Sphäroiden pro Platte.
Zu den Hauptmerkmalen gehören 8 unabhängige Kanäle pro Platte, Kompatibilität mit 96-/384-Well-Platten für Hochdurchsatz-Screening sowie eine Mikroskop-Montagefähigkeit. Die Plattform hat interne Tests und Validierungen durchlaufen, und die Entwicklung für die Massenproduktion läuft derzeit.
Der Start richtet sich an den wachsenden globalen 3D-Zellkultur-Markt, der im Jahr 2025 auf 2,32 Milliarden USD geschätzt wird und bis 2030 auf 4,71 Milliarden USD anwachsen soll, mit einer CAGR von 15,6%.
Advanced Biomed (ناسداك: ADVB) أطلقت A+PerfusC™، منصة مدمجة للزراعة الخلوية ثلاثية الأبعاد عبر التروية مصممة لتطبيقات الطب الدقيق واكتشاف الأدوية. النظام يتميز بتصميم مدمج وشامل يدعم حتى 12 يومًا من الزراعة المستمرة بدون تدخل بشري مع قدرة على 4,800 كرة ورمية نموذجية/ورمية للأورام لكللوح
تشمل الميزات الرئيسية 8 قنوات مستقلة لكل لوح، وتوافق مع أطباق 96/384 فاصل لفرز عالي الأداء، وإمكانية تثبيت المِجهر. أكملت المنصة الاختبارات الداخلية والاعتماد، وتطوير الإنتاج الضخم جارٍ حاليًا.
الإطلاق يستهدف السوق العالمية المتنامي لـ ثقافة الخلايا ثلاثية الأبعاد، والذي يقدَّر بقيمة 2.32 مليار دولار في 2025 ومن المتوقع أن يصل إلى 4.71 مليار دولار بحلول 2030 بمعدل نمو سنوي مركب قدره 15.6%.
Advanced Biomed（纳斯达克：ADVB） 推出 A+PerfusC™，这是一款面向精准医疗与药物发现应用的集成灌注三维细胞培养平台。该系统设计紧凑、集成度高，支持最长12天的连续无手动干预培养，每板可容纳4,800个肿瘤球体。
关键特性包括每板 8条独立通道、兼容96孔/384孔板以实现高通量筛选，以及显微镜安装能力。该平台已完成内部测试与验证，现正推进大规模生产开发。
此次发布瞄准增长中的全球3D细胞培养市场，预计在2025年的市场规模为23.2亿美元，到2030年预计达到47.1亿美元，年复合增长率为15.6%。
- None.
- Mass production development and quality control standards still pending
- System expansion feature for controlling multiple incubators still undergoing development
Insights
Advanced Biomed's new 3D cell culture platform offers significant technical advantages in a growing $2.32B market projected to reach $4.71B by 2030.
Advanced Biomed has launched A+PerfusC™, a sophisticated integrated perfusion 3D cell culture platform that addresses critical limitations of traditional cell culture methods. The system's key technical differentiators include its compact all-in-one design with microscope mounting capability, continuous automated perfusion for up to 12 days without manual intervention, and impressive capacity of 4,800 tumor spheroids per plate across 8 independent channels.
The platform solves fundamental challenges in 3D cell culture by ensuring uniform nutrient delivery and waste removal, which directly enhances spheroid formation, cell viability, and experimental reproducibility. These improvements are particularly valuable for generating more predictive drug response data compared to conventional methods.
The product targets high-value applications including personalized oncology, drug screening, regenerative medicine, and stem cell research. The timing is strategically sound, entering a market valued at
The company's development roadmap suggests potential for further value creation through high-throughput scaling and AI-driven analytics integration. While the product has completed internal validation with finalized design, investors should note that mass production development and quality control standardization remain as steps before full commercialization.
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC™ system, a compact, all‑in‑one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro.
(A+PerfusC™ 3D System-a perfusion-based 3D cell culture in a compact incubator)
The A+PerfusC™ platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real‑time observation. The system supports up to 12 days of continuous, hands‑free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability. The system is characterized and proved by:
- 8 independent channel/patient source per plate
- 600 tumor spheroids per row for one patient
- 4,800 tumor spheroids per plate
- Easy to transfer into 96 or 384 well plate for high-throughput drug screening
- Easy to mount on microscopy platforms
- Expandable- control platform supporting up to four incubators. (undergoing)
A+PerfusC™ system and its 3D culture plate (consumable) have passed internal testing and validation with design finalized. Currently the Company is advancing its mass-production development. Its commercialization can be achieved following mass-production development finalized and quality control standards established.
Potential applications include personalized oncology research, invitro drug screening, regenerative medicine, organoid studies, and stem cell research. According to Mordor Intelligence, the global 3D cell culture market was valued at USD 2.32 billion in 2025 and is projected to exceed USD 4.71 billion by 2030, representing a compound annual growth rate of over
Dr. Yi Lu, CEO of the Company, commented: “Traditional static cell culture often leads to uneven nutrient delivery and waste buildup, compromising cell growth, viability, and reproducibility. Notably, in certain high-density culture scenarios, particularly within multi-microwell 3D culture devices, metabolic waste can rapidly accumulate inside the micro-grooves, requiring more frequent medium replacement which can be labor-intensive to preserve culture quality.”
“Our 3D culture system evenly delivers nutrients and clears waste, reducing cellular stress, boosting long-term viability, and more accurately mimicking human tissue complexity for improved drug response and disease modeling.”
“The Company plans to scale up the A+PerfusC™ system for high‑throughput use and integrate imaging with AI‑driven analytics, aiming to accelerate tumor profiling, refine cell therapy protocols, and advance personalized treatment development.”
About Advanced Biomed Inc.
Advanced Biomed Inc. is a Nevada‑incorporated holding company specializing in innovative biomedical technologies for cancer detection and precision medicine.
Operating through subsidiaries in Taiwan, Hong Kong, and Mainland China, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in China and plans for future global expansion.
For more information, please visit: www.advanbiomed.com.
Forward‑Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email: info@advbiomedicine.com
invest@advbiomedicine.com
FAQ
What is Advanced Biomed's A+PerfusC™ system and what does it do?
What is the market potential for ADVB's new 3D cell culture platform?
What are the key features of Advanced Biomed's A+PerfusC™ platform?
When will ADVB's A+PerfusC™ system be commercially available?
What applications does Advanced Biomed's A+PerfusC™ system target?
